---
title: "SpyGlass Pharma, Inc. (SGP.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/SGP.US/overview.md"
symbol: "SGP.US"
name: "SpyGlass Pharma, Inc."
parent: "https://longbridge.com/zh-CN/quote/SGP.US.md"
datetime: "2026-04-15T03:09:00.425Z"
locales:
  - [en](https://longbridge.com/en/quote/SGP.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SGP.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SGP.US/overview.md)
---

# SpyGlass Pharma, Inc. (SGP.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 制药 |
| 交易所 | US Market |
| 地址 | 27061 Aliso Creek Road, Suite 100, Aliso Viejo, California, United States |
| 官网 | [www.spyglasspharma.com](https://www.spyglasspharma.com) |

## 公司简介

SpyGlass Pharma, Inc. 是一家生物制药公司，专注于为患有慢性眼部疾病的患者提供治疗和药物输送。该公司开发了 Bimatoprost 药物垫-IOL 系统（BIM-IOL 系统），该系统由新型的专有药物垫和一种眼内镜片（IOL）组成，旨在在常规白内障手术中植入，以降低患者的眼内压（IOP）。此外，它还开发了一种非 IOL 基础的环形缓释植入物，含有比马前列素

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Malik Y. Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman |
| Patrick H. Mooney | CEO & Director |
| Chetan Pujara | Chief Research & Development Officer |
| Glenn Sussman | Co-founder & Chief Technology Advisor |
| Jean-Frederic Viret | Chief Financial Officer |
| Zachary Scheiner | Independent Director |
| Bilal Arshad Khan | Independent Director |
| Elizabeth G. O’Farrell | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| RA Capital Management, L.P. | 24.00% | 2026-02-09 |
| New Enterprise Associates, Inc. | 22.12% | 2026-02-13 |
| Vensana Capital Management, LLC | 9.90% | 2026-02-09 |
| Sands Capital Ventures, LLC | 7.48% | 2026-02-06 |
| Gilde Healthcare Partners B.V. | 6.54% | 2026-02-09 |
| Samsara BioCapital LLC | 6.31% | 2026-02-09 |
| Malik Y. Kahook | 2.61% | 2026-02-06 |
| Franklin Resources, Inc. | 0.90% | 2026-02-28 |
| Bilal Khan | 0.83% | 2026-02-09 |
| Patrick Mooney | 0.55% | 2026-02-06 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**